期刊文献+

新型GLP-1受体激动剂Lixisenatide的研究进展 被引量:2

下载PDF
导出
摘要 据2012年国际糖尿病联盟的最新统计数据显示,2011年全球糖尿病人数高达3.66亿人,预计到2030年将上升到5.52亿人,Ⅱ型糖尿病患者占其中的90%以上。中国是全球糖尿病人数最多、增长速率最快的国家,且血糖控制情况较差,整体达标率(HbA1c6.5%)仅为26.8%,这可能与各类降糖药的副作用较大,如低血糖反应、体重增加等,致使患者不能坚持用药有关。糖尿病早已成为严重威胁人类健康的公共卫生问题,并对社会及经济发展造成沉重的负担。
出处 《中国现代医药杂志》 2014年第4期105-107,共3页 Modern Medicine Journal of China
基金 贵州省免疫学研究生教育创新基地2012年重点培育项目(编号:201105)
  • 相关文献

参考文献15

  • 1Whiting DR, Guariguata L,Weil C, et al. IDF diabetes atlas : glob- al estimates of the prevalence of Diabetes for 2011 and 2030[J]. Diabetes Res Clin Pract,2011,94(3) :311-321.
  • 2Pan C,Yang W,Jia W,et al. Management of Chinese patients with type 2 diabetes, 1998-2006:the Diabcare -China surveys[J]. Curt Med Res Opin,2009,25(1 ) :39-45.
  • 3Nauck MA,Heimesaat MM,Behle K, et al.Effeets of glueagon-like peptide-1 on counterregulatory hormone responses,cognitive founetion,and insulin secretion during hyperinsulinemic ,stepped hypoglycemic clamp experiments in healthy volunteers[J].Clin En- doerinol Metab ,2002,87 : 1239-1246.
  • 4Laurie L, Baggio, Daniel J,et al. Biology of ineretins:GLP-1 and GIP[J]. Gastroenterology,2007,132:2131-2157.
  • 5Meier JJ.GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus[J]. Nature Reviews Endocrinology,2012, 8 : 728-742.
  • 6Christensen M,Knop FK,Holst JJ,et aL Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2diabetes mellitus [J]. IDrugs, 2009,12 : 503-513.
  • 7Thorkildsen C,Neve S,Larsen BD,et al. Glucagon-like peptide 1 receptor agonist ZP10 A increases insulin mRNA expression and prevents diabetic progression in db/db mice[J]. J Pharmacol Exp Ther, 2003,307 : 490-496.
  • 8Distiller LA,Ruus P. on behalf of the ACT6011 Study Group. Phar- macokinetics and pharmaeodynamics of a new GLP-1 agonist AVE0010 in type 2 diabetes patients. Diabetes,2008,57,1:A154-155.
  • 9Liu Y-H ,Ruus P. Pharmacokinetics and safety of the GLP-1 ag- onist AVE0010 in patients with renal impairment. Abstract 557-P presented at the 69th Scientific Sessions of the American Dia- betes Association,2009:5-9.
  • 10ClinicalTrials.gov,Identifier NCT00688701 ,GLP-1 agonist AVE0010 in patients with type 2 diabetes for glycemic control and safety e- valuation in monotherapy (GETGOAL-MONO). Available at:http'.// clinicaltrials.gov/ct2/show/NCT00688701?term =lixisenatidede& rank=8 (accessed December 19, 2011 ).

同被引文献9

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部